Table 2.
Children’s health status and vaccination coverage in rural Andean Peru
| IHIP+ | IHIP | ECD | Control | |||||
|---|---|---|---|---|---|---|---|---|
| N | Mean (SD) or % (N) |
N | Mean (SD) or % (N) |
N | Mean (SD) or % (N) |
N | Mean (SD) or % (N) |
|
| Anthropometricsa | 78 | 79 | 79 | 81 | ||||
| Height-for-age, Z-values | 64 | − 1.3 (1.1) | 50 | −1.0 (0.9) | 64 | −1.5 (1.1) | 61 | −1.4 (0.8) |
| Stunting | 64 | 17.2% (11) | 50 | 9.8% (5) | 64 | 36.9% (24) | 61 | 18.0% (11) |
| Weight-for-age, Z-scores | 64 | −0.4 (1.0) | 51 | − 0.1 (0.8) | 65 | − 0.6 (0.9) | 61 | − 0.5 (0.9) |
| Underweight | 64 | 6.3% (4) | 51 | 2.0% (1) | 65 | 10.8% (7) | 61 | 4.9% (3) |
| Children’s health status | 78 | 79 | 79 | 81 | ||||
| Weight at birth | 3.1 (0.6) | 3 (0.5) | 3.1 (0.5) | 3.1 (0.4) | ||||
| Diarrhoea, two-weeks prevalence | 18.4% (14) | 22.8% (18) | 19% (15) | 26.3% (21) | ||||
| Fever, two-weeks prevalence | 21.8% (17) | 21.5% (17) | 25.3% (20) | 23.5% (19) | ||||
| Cough, two-weeks prevalence | 35.1% (27) | 31.7% (25) | 39.2% (31) | 29.1% (23) | ||||
| Children with no health coverage | 10.3% (8) | 10.1% (8) | 5.1% (4) | 1.2% (1) | ||||
| Children’s vaccination | 78 | 79 | 79 | 81 | ||||
| Tuberculosis (BCG) | 77 | 89.6% (69) | 91.1% (72) | 94.9% (75) | 95.1% (77) | |||
| Measles | 77 | 50.7% (39) | 78 | 60.3% (47) | 77 | 67.5% (52) | 64.2% (52) | |
| Diphtheria, convulsive cough and tetanus (DTP)b | ||||||||
| 1st dose | 77 | 96.1% (74) | 94.9% (75) | 98.7% (78) | 95.1% (77) | |||
| 2nd dose | 73 | 90.4% (66) | 77 | 89.6% (69) | 97.5% (77) | 79 | 93.7% (74) | |
| 3rd dose | 64 | 87.5% (56) | 69 | 79.7% (55) | 72 | 93.1% (67) | 73 | 82.2% (60) |
| Polio (OPV)c | ||||||||
| 1st dose | 77 | 96.1% (74) | 96.2% (76) | 98.7% (78) | 96.3% (78) | |||
| 2nd dose | 73 | 89.0% (65) | 77 | 90.9% (70) | 97.5% (77) | 79 | 93.7% (74) | |
| 3rd dose | 64 | 78.1% (50) | 69 | 79.7% (55) | 72 | 90.3% (65) | 73 | 75.3% (55) |
| Influenza | 77 | 62.3% (48) | 63.3% (50) | 81.0% (64) | 69.1% (56) | |||
| Hepatitis B | 77 | 62.3% (48) | 54.4% (43) | 79.8% (63) | 69.1% (56) | |||
| Recommended vaccines 6–11 months | 23 | 28 | 24 | 15 | ||||
| All vaccinesd | 69.6% (16) | 60.7% (17) | 87.5% (21) | 40% (6) | ||||
| No vaccines | 0% (0) | 7.1% (2) | 0% (0) | 0% (0) | ||||
| Recommended vaccines 12–24 months | 41 | 41 | 48 | 58 | ||||
| All vaccinese | 68.3% (28) | 70.7% (29) | 46 | 84.8% (39) | 70.7% (41) | |||
| No vaccines | 2.4% (1) | 4.9% (2) | 2.1% (1) | 0% (0) | ||||
| Portable pulse oximetry assessmentf | 64 | 59 | 63 | 68 | ||||
| Oxygen saturation (SpO2) | 93.5 (2.8) | 94.2 (2.5) | 93.8 (3.8) | 93.8 (2.8) | ||||
| Respiratory rate per/min. | 27.7 (3.7) | 26.4 (3.0) | 27.2 (2.7) | 27.3 (3.1) | ||||
1As estimated on 15th December 2015 (±31 days). If several estimates within the range were available, the one closest to 15th of December was selected
bDPT vaccination: 1st dose: 2 month; 2nd dose: 4 month; and 3rd dose: 6 month
c Polio vaccination: 1st dose: 2 month; 2nd dose: 4 month; and 3rd dose: 6 month
d It includes BCG (one dose), DTP (three doses) and OPV (three doses)
e It includes BCG (one dose), DTP (three doses), OPV (three doses) and measles (one dose)
f Results from children with no observable danger signs, fever, cough and difficulty to breath at the time of the assessment